The selection of Heme oxygenase-1 (HMOX1) and the enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) as therapeutic targets is grounded in their pivotal roles in promoting tumor progression and treatment resistance. The gene discussed is PFKFB4; the disease is neoplasm.